CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
LY2127399 (Tabalumab) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01253226
NCT01253226Phase 1Completed
CompareCT.gov

Multiple-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate

Eli Lilly and Company·interventional·Posted Dec 3, 2010·Updated Oct 23, 2018

In Brief

A Phase 1 clinical trial evaluating LY2127399 (Tabalumab) and Placebo for Rheumatoid Arthritis. Completed, enrolled 32 participants across 10 sites.

Detailed Summary

This study will evaluate the safety and tolerability of multiple doses of LY2127399 (tabalumab) in Japanese participants with RA. The study consists of a 20-week treatment period. All participants will be followed for up to 12 weeks after the last study drug administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 3, 2010
Enrollment StartSep 1, 2009
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 15.6 years ago

Interventions

LY2127399 (Tabalumab)drug

Administered subcutaneously

Placebodrug

Administered subcutaneously